The Centre for Veterinary Vaccine Innovation and Manufacturing (CVIM) - Design and Build

A joint initiative between the Biotechnology and Biological Sciences Research Council (BBSRC), part of UK Research and Innovation (UKRI), the Foreign, Commonwealth and Development Office (FCDO) and the Bill & Melinda Gates Foundation will see the creation of a new centre at The Pirbright Institute designed to accelerate the development of animal vaccines to combat emerging and urgent infectious diseases.

The consequences of livestock disease can be catastrophic. As well as posing a very real risk to global food security and international trade, livestock disease also presents a significant threat to global human health due to its pandemic potential.

While the UK remains a world-leader in the early-stage development of vaccines for both human and veterinary medicine, globally we need to strengthen our collective capacity to translate scientific discoveries into solutions for the most challenging veterinary infectious diseases.

The new Centre for Veterinary Vaccine Innovation and Manufacturing (CVIM) will bridge the gaps between research and expertise in process development and manufacturing while strengthening the UK's own emergency response capacity and capability. It will bring about tangible health and economic benefits by focusing on diseases prevalent in low- and middle-income countries.

Procurement Route - Design and Build

Tender Strategy - 'Open Procedure' Single Stage Tender

Design Stage - Stage 3

Form of Contract - NEC4 Option A: Fixed Price with Activity Schedule

The successful Contractor will be responsible for designing and building a c.590m2 new-build facility for The Pirbright Institute, c.461m2 of functional space on the ground floor and c.129m2 of plant space on the first floor.

1) General building outline: New build facility, 590m2, two story above ground, with all functions on ground floor, and plant room on the first floor, comprising of 1 nr GMP cleanroom (ISO007), 1 nr cold-room (CNC), 1 nr freezer room, RM Storage and receipt areas, 1 nr QC Micro lab (CNC), 1 nr QC lab (CNC), a write up area/office and all supporting areas including a plant room and associated external works.

2) The building will be constructed within the existing Pirbright site.

3) Achieve Part L - 2, target for Net Zero Carbon (NZC).

The design of the facility will include biocontainment (ACDP CL2/SAPO2/GMO2), BREEAM: Very Good, cleanrooms (up to ISO7), good manufacturing practice (GMP), net-zero carbon and equity, diversity and inclusion (EDI). The project team have developed the RIBA stage 3 design in accordance with the end-user requirements.

The project team that developed the RIBA Stage 3 design in conjunction with the end-user requirements were as follows.

• Project Manager - Currie and Brown • Cost Manager - Turner and Townsend • Multi-Disciplinary Design Consultant / CMT - Scitech

Additional information: Please note that Appendix 1 - Confidentiality Agreement must be completed, signed, and emailed to [email protected] asap. Then and only then will access to the full ITT package (Appendices 4 & 5) be granted to the requester.